Integrative analyses identify susceptibility genes underlying COVID-19 hospitalization

Gita A. Pathak, Kritika Singh, Tyne W. Miller‐Fleming, Frank R. Wendt, Nava Ehsan, Kangcheng Hou, Ruth Johnson, Zeyun Lu, Shyamalika Gopalan, Loic Yengo Dimbou, Pejman Mohammadi, Bogdan Paşaniuc, Renato Polimanti, Lea K. Davis, Nicholas Mancuso

Abstract

Despite rapid progress in characterizing the role of host genetics in SARS-Cov-2 infection, there is limited understanding of genes and pathways that contribute to COVID-19. Here, we integrated a genome-wide association study of COVID-19 hospitalization (7,885 cases and 961,804 controls from COVID-19 Host Genetics Initiative) with mRNA expression, splicing, and protein levels (n=18,502). We identified 27 genes related to inflammation and coagulation pathways whose genetically predicted expression was associated with COVID-19 hospitalization. We functionally characterized the 27 genes using phenome- and laboratory-wide association scans in Vanderbilt Biobank (BioVU; n=85,460) and identified coagulation-related clinical symptoms, immunologic, and blood-cell-related biomarkers. We replicated these findings across trans-ethnic studies and observed consistent effects in individuals of diverse ancestral backgrounds in BioVU, pan-UK Biobank, and Biobank Japan. Our study highlights putative causal genes impacting COVID-19 severity and symptomology through the host inflammatory response.

Introduction

While clinical factors such as age and pre-existing comorbidities significantly increase the risk of severe COVID-19, they do not fully account for the extreme variability in patient outcomes. Genomic studies have begun to uncover the host genetic architecture of SARS-CoV-2 susceptibility, yet many identified variants reside in non-coding regions, complicating the transition from genetic association to functional understanding. This study aims to bridge this gap by integrating genome-wide association study (GWAS) data with molecular quantitative trait loci (QTL) to identify specific susceptibility genes and the biological pathways—such as inflammation and coagulation—that drive disease severity.

Methods and Data

The researchers employed an integrative multi-omic approach to prioritize causal genes. The primary GWAS data was sourced from the COVID-19 Host Genetics Initiative (HGI) Freeze 4, encompassing 7,885 hospitalized cases. To identify functional mechanisms, the team utilized:

  • TWAS, spTWAS, and PWAS: Transcriptome-, Splicing-, and Proteome-Wide Association Studies were conducted using S-PrediXcan and S-MultiXcan. These tools integrated GWAS statistics with reference models from GTEx v8 (49 tissues) and the INTERVAL study (plasma proteins) to predict how genetic variants influence mRNA expression, alternative splicing, and protein abundance.
  • Functional Characterization: Phenome-Wide (PheWAS) and Laboratory-Wide Association Scans (LabWAS) were performed using electronic health records (EHR) from the Vanderbilt Biobank (BioVU; n=85,460) to link identified genes to clinical phenotypes and biomarkers.
  • Cross-Ancestry Validation: Findings were replicated using data from the Pan-UK Biobank and Biobank Japan to ensure generalizability across diverse global populations.

Results

The integrative analysis identified 27 susceptibility genes across 13 independent genomic regions. These genes are primarily involved in host inflammatory responses (cytokine signaling) and blood coagulation pathways, providing a genetic basis for the clinical observations of "cytokine storms" and thrombotic complications in severe cases.

Genomic landscape of identified susceptibility genes across multiple molecular levels.

Two genes, ABO and OAS1, emerged as high-confidence hits, showing significant associations across mRNA expression, splicing, and protein levels. The ABO gene, which determines blood type, was linked to levels of Coagulation Factor VIII and von Willebrand factor, suggesting a mechanism for the increased clotting risk in certain individuals. Additionally, lower predicted expression of IFNAR2 (part of the interferon-alpha/beta receptor) was associated with higher hospitalization risk, supporting the role of deficient early antiviral responses in disease progression.

TWAS results highlighting significant gene-tissue associations for COVID-19 hospitalization.

The PheWAS identified 40 clinical phenotypes, predominantly circulatory and infectious diseases, while the LabWAS highlighted 32 laboratory traits, including platelet counts and ferritin levels, associated with these 27 genes. Notably, the effects of these genes were remarkably consistent across different ancestral backgrounds, suggesting universal core biological mechanisms for COVID-19 severity.

Discussion

This study provides a comprehensive map of the genetic drivers of COVID-19 hospitalization. By identifying 27 genes linked to inflammation and coagulation, the research offers potential targets for therapeutic intervention. However, limitations remain, including the reliance on European-ancestry reference models for TWAS/PWAS and the use of bulk tissue data, which may obscure cell-type-specific effects (e.g., in alveolar macrophages). Future research utilizing single-cell transcriptomics and functional validation in laboratory models will be essential to further refine these findings and translate them into clinical applications.

Summary updated

Abstract

Despite rapid progress in characterizing the role of host genetics in SARS-Cov-2 infection, there is limited understanding of genes and pathways that contribute to COVID-19. Here, we integrated a genome-wide association study of COVID-19 hospitalization (7,885 cases and 961,804 controls from COVID-19 Host Genetics Initiative) with mRNA expression, splicing, and protein levels (n=18,502). We identified 27 genes related to inflammation and coagulation pathways whose genetically predicted expression was associated with COVID-19 hospitalization. We functionally characterized the 27 genes using phenome- and laboratory-wide association scans in Vanderbilt Biobank (BioVU; n=85,460) and identified coagulation-related clinical symptoms, immunologic, and blood-cell-related biomarkers. We replicated these findings across trans-ethnic studies and observed consistent effects in individuals of diverse ancestral backgrounds in BioVU, pan-UK Biobank, and Biobank Japan. Our study highlights putative causal genes impacting COVID-19 severity and symptomology through the host inflammatory response.
BibTeX
@inproceedings{pathak2021integrative,
  author = {Gita A. Pathak and Kritika Singh and Tyne W. Miller‐Fleming and Frank R. Wendt and Nava Ehsan and Kangcheng Hou and Ruth Johnson and Zeyun Lu and Shyamalika Gopalan and Loic Yengo Dimbou and Pejman Mohammadi and Bogdan Paşaniuc and Renato Polimanti and Lea K. Davis and Nicholas Mancuso},
  title = {{Integrative analyses identify susceptibility genes underlying COVID-19 hospitalization}},
  booktitle = {Amia},
  year = {2021},
}
Figure